GENMAB A/S -SP ADR (NASDAQ:GMAB) was identified by our screener as a strong growth stock with a promising technical setup. The company combines solid fundamentals with improving price action, making it worth a closer look.
Strong Growth Fundamentals
Revenue & Earnings Growth: GMAB has delivered impressive revenue growth of 30.67% over the past year, with earnings per share (EPS) expanding by 24.67%. The company’s long-term EPS growth averages 29.12%, well above industry standards.
Profitability: With a profit margin of 36.44% and an operating margin of 32.18%, GMAB ranks among the top performers in the biotechnology sector.
Financial Health: The company maintains a strong balance sheet, reflected in a high Altman-Z score of 7.96 and minimal debt (Debt/Equity ratio of 0.03).
Attractive Valuation
Despite its strong growth, GMAB appears undervalued compared to peers:
P/E Ratio: At 12.93, well below the industry average of 58.85.
Forward P/E: 10.47, suggesting further earnings growth is not fully priced in.
Technical Setup
Recent Strength: The stock has shown positive short-term momentum, trading above key moving averages.
Support Levels: Strong support exists near $19.39-$20.42, providing a potential floor for pullbacks.
Resistance Breakout: A move above $21.77 could signal further upside, with additional resistance near $22.60 and $23.71.
GENMAB A/S (NASDAQ:GMAB) offers strong earnings growth, high profitability, and an attractive valuation, making it a solid pick for GARP investors following Peter Lynch's strategy.